Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track NCEL with free AI briefings, catalyst countdowns, and dilution alerts.

NCEL · NewcelX Ltd.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$710,000 Cash on Hand
1.7mo Cash Runway
Follow NCEL by email Get an email when NCEL reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about NCEL, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

NCEL holds $710,000 in cash and short-term investments and burns about $1.3M/quarter from operations, an estimated runway of 1.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 70 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NCEL files for a raise →

👥 Who Owns NCEL

Insiders 27.3% Other 5%+ holders 39% Institutions (7 holders) 1.3% Public and other holders 32.4%
HolderTypeShares% of sharesAs of
League Jinn Sarl 5%+ holder (13D) 1,316,267 27.44% 2026-04-27
Michel Revel
CSO and Director, Director, 10% owner · +76,363 options
Insider 957,530 19.96% 2026-04-27
Ronald Hafner 5%+ holder (13D) 557,131 11.61% 2025-05-22
Ronen Twito
Chairman and CEO, Director
Insider 272,399 5.68% 2026-03-18
Olivier Samuel
Director · +114,545 options
Insider 81,818 1.71% 2026-04-27

Share count 4,797,505 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full NCEL picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NCEL and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.